

Curriculum Vitae
Michael C. Tobes, MD, PhD, FACC

Address: 1505 South Palestine
Athens, Texas 75751

Telephone: Office (903)-675-6800
Fax (903)-670-1134

Date of Birth: October 7, 1948
Detroit, Michigan

Practice

1997-Present Cardiovascular Associates of East Texas, P.A., Athens, Texas

Education

General Education

1976 - 1979 University of Michigan - Ann Arbor, Michigan
Post Doctoral Degree - Nuclear Medicine

1972 - 1976 University of Michigan - Ann Arbor, Michigan
Doctor of Philosophy Degree, (Biological Chemistry)

1970 - 1972 University of Michigan - Ann Arbor, Michigan
Master of Science Degree, (Biochemistry)

1966 - 1970 Michigan State University - East Lansing Michigan
Bachelor of Science Degree (Biochemistry)

Medical Education

1993 - 1997 Fellowship – Cardiology
Henry Ford Hospital, Division of Cardiovascular Medicine

1990 - 1993 Medical Residency - Internal Medicine
Pennsylvania State University
The Milton S. Hershey Medical Center

1988 - 1990 University of Miami School of Medicine - Miami, Florida
Doctor of Philosophy to Doctor of Medicine Program

Board Certification

2004 Board Certification in Nuclear Cardiology

Licensure

1997 State of Texas No. K2607

1994 State of Michigan

Hospital Appointments

East Texas medical Center, Athens, Texas

Memberships

1997-Present Member, Texas Medical Association

1997-Present Member, Henderson County Medical Society

1997-Present Member, Medicine Section, East Texas Medical Center, Athens, Texas

1997-Present Member, Pharmacy and Therapeutic and Infective Control Committee

1988 Member, Computer Council of the Society of Nuclear Medicine

1985-1988 Member, Radiopharmaceutical Science Council of the Society of Nuclear Medicine

1983-1987 Member, American Chemical Society

1983-1985 Member, Advisory Committee on Primary Research Appointments, Promotions and Titles (APRAPT) of the University of Michigan Medical School

1981-1988 Member, Society of Nuclear Medicine

1981/1996/1987 Referee Journal of Nuclear Medicine

1978-1987 Member, American Association of the Advancement of Science

Administrative Duties

1998-Present Director, Cardiopulmonary Laboratory
East Texas Medical Center, Athens, Texas

1979-1985 Director, Nuclear Medicine Biochemistry Research Unit, Department of
Internal Medicine, Ann Arbor, Michigan

Teaching Appointments

1979-1984 E.I.H. 509, Environmental Carcinogenesis –
Department of Industrial and Environmental
Health, Director – Dr. Bruce Chin

Professional Appointments

1985 - 1988 Member of Technical Staff - Medical Diagnosis Systems Laboratory,
AT&T Bell Laboratories, Middletown, New Jersey

1981 - 1985 Assistant Research Scientist - Department of Internal Medicine, Division of Nuclear
Medicine, The University of Michigan, Ann Arbor, Michigan

1979 - 1981 Research Investigator - Department of Internal Medicine, Division of Nuclear Medicine,
The University of Michigan, Ann Arbor Michigan

1976 - 1979 Postdoctoral Scholar – Department of Biological Chemistry
Director – Dr. Merle Mason, Department of Internal Medicine,
Director - Dr. William H. Beierwaltes,
The University of Michigan, Ann Arbor, Michigan

Research

Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus
Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary
syndrome without ST segment elevation.

Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal
System.

Co-Investigator - REPLACE II - A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical
Events, Part 2: REPLACE-2 (TMC-BIV-01-03)

Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary
Intervention Linking Angiomax to Reduced Clinical Events.

Co-Investigator – ER-TIMI 19 – A Phase IV, Open-Label Trial of Prehospital Administration of Retavase®
for ST elevation MI – the Early Retavase® (ER) – TIMI 19 Trial.

Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter
trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to
reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral
myocardial infarction.

Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A phase III, randomized, open-label trial evaluating
the efficacy and safety of ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavase™ /
Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial
infarction.

Co-Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.

Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label-community-based clinical practice study of Niaspan in patients with hyperlipidemia.

Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non-Q wave myocardial infarction.

Co-investigator-PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.

Participant, National Registry of Myocardial Infarction 3, East Texas Medical Center – Athens, TX

Co-Principal Investigator - NIH Grant - HL-27555: "Heart Imaging Agents: A Structural Mechanistic Study".

Co-Principal Investigator – NIAMDD Grant 5-R01-AM-21477.

Co-Principal Investigator – DOE Grant DE-AC02-76EV02031: "Radiopharmaceuticals for Diagnosis and Treatment".

Co-Principal Investigator - NIAMDD Grant AM-21477: Radionuclide Adrenal Imaging in Hypertension".

Co-Investigator - NIH Grant 1-510-RR-02387: "Radionuclide Tomographic Camera and Dedicated Computer".

Co-Principal Investigator - Merrell Dow Pharmaceuticals, Inc., Merrell Research Center Grant: "A Phase I Clinical Study of Combination of DFMO and MGBG: Pharmacokinetic, Cellular, Biochemical, Pharmacological and Cytokinetic Effects".

Principal Investigator - NIH Grant - 1R01-CA-32878: "Enzyme Inhibitors as Radiopharmaceutical Agents".

Co-Investigator - DOE Grant - DE-AC02-76EV02031: Radiopharmaceuticals for Diagnosis and Treatment."

Co-Principal Investigator - NIH Grant - 1-R01-HL-27555: "Heart Imaging Agents: A Structural-Mechanistic Study".

Co-Principal Investigator - NIH Grant - 1-RO1-CA-27244: "Mechanism based Inhibitors of Diamine Oxidase".

Public Service

- 3/10/1982 Speaker and panelist for a review session on "Recent Research on Biological Properties and Environmental Fate of MBOCA (4,4'-methylene-bis (2-chloroniline))" sponsored by the State of Michigan Toxic Substance Control Commission in Lansing, Michigan
- 1982 American Association for the Advancement of Science Volunteers at Cranbook Institute of Science

Invited Lectures

- 04/20/1999 East Texas Medical Center - Tyler, Department of Medical Education: "Current Management Strategies for Congestive Heart Failure"
- 07/09/1997 East Texas Medical Center - Athens, Medical Staff Meeting: 'The Management of Heart Failure in the '90s."
- 05/28/1985 The Procter & Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio: "Pharmacology of a Sympathoadrenal Imaging Agent"
- 11/26/1984 Department of Internal Medicine, Division of Hypertension, The University of Michigan, Ann Arbor, Michigan: "Meta-iodobenzylguanidine (MIBG): A potentially all-purpose sympathoadrenal imaging agent"
- 03/25/1982 The Interdepartmental Program in Medicinal Chemistry, College of Pharmacy, The University of Michigan, Ann Arbor, Michigan: "Enzyme Inhibitors as Radiopharmaceuticals: Metyrapone Analogues"